Mete Gundog
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mete Gundog has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Celalettin Eroğlu
Department of Radiation Oncology, Erciyes University Medical Faculty, Kayseri, Turkey
4 shared publications - Esin Kiraz
Faculty of Medicine, Department of Radiation Oncology Erciyes University Kayseri Turkey
3 shared publications Hatice Basaran
Medicine Faculty Department of Radiation Oncology Erciyes University Kayseri Turkey
3 shared publications- Hatice Basaran Goksen
Department of Radiation Oncology, Kayseri City Education and Research Hospital, Kayseri, Turkey
3 shared publications - Oktay Bozkurt
Department of Medical Oncology, Erciyes University, Kayseri 38039, Turkey
3 shared publications - Imdat Yuce
Faculty of Medicine, Department of Otorhinolaryngology, Erciyes University, Kayseri, Turkey
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (8) , e72158
The Impact of the G8 Score on Survival Outcomes in Patients With Head and Neck Cancer Undergoing Concurrent Radiotherapy With Cetuximab due to Contraindications With Cisplatin
Purpose: Patients unable to receive cisplatin due to age, comorbidities, or reduced performance status are commonly treated with concurrent radiotherapy (RT) and cetuximab. This study evaluated the prognostic significance of the Geriatric 8 (G8) score and the Charlson Comorbidity Index (CCI) in predicting survival outcomes in this population. Methods: We retrospectively analyzed data from 52 patients with locally advanced or loco‐regional recurrent head and neck squamous cell carcinoma (HNSCC) who were treated with RT and cetuximab between 2011 and 2024. Patients with p16‐positive oropharyngeal or nasopharyngeal cancers were excluded. Overall survival (OS) and cancer‐specific survival (CSS) were assessed according to G8 and CCI scores using ROC analysis, Kaplan–Meier curves, and Cox regression. Results: The median follow‐up was 50 months. A G8 cut‐off of 9.75 was identified (AUC: 0.713, p < 0.01). Patients with G8 ≥ 9.75 showed significantly improved OS (median: 47 vs. 7 months, p < 0.01) and 4‐year CSS (66% vs. 32%, p < 0.01). In the definitive treatment group, 4‐year CSS was 68% in high‐G8 patients vs. 42% in low‐G8 patients. In the recurrence group, 4‐year CSS was 63% among high‐G8 patients, whereas no patient with a low G8 score survived beyond 4 years. Multivariate analysis identified G8 < 9.75 (HR: 4.72, p < 0.01) and RT dose < 60 Gy (HR: 3.01, p = 0.01) as independent predictors of poor OS. No significant association was observed between CCI and survival. Conclusion: The G8 score is a valuable prognostic tool for cisplatin‐ineligible HNSCC patients treated with RT and cetuximab. Low G8 scores were strongly associated with worse outcomes, highlighting the need for alternative therapeutic strategies in this high‐risk subgroup.
- 30 July 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (8) , e72158
Open AccessThe Impact of the G8 Score on Survival Outcomes in Patients With Head and Neck Cancer Undergoing Concurrent Radiotherapy With Cetuximab due to Contraindications With Cisplatin
Purpose: Patients unable to receive cisplatin due to age, comorbidities, or reduced performance status are commonly treated with concurrent radiotherapy (RT) and cetuximab. This study evaluated the prognostic significance of the Geriatric 8 (G8) score and the Charlson Comorbidity Index (CCI) in predicting survival outcomes in this population. Methods: We retrospectively analyzed data from 52 patients with locally advanced or loco‐regional recurrent head and neck squamous cell carcinoma (HNSCC) who were treated with RT and cetuximab between 2011 and 2024. Patients with p16‐positive oropharyngeal or nasopharyngeal cancers were excluded. Overall survival (OS) and cancer‐specific survival (CSS) were assessed according to G8 and CCI scores using ROC analysis, Kaplan–Meier curves, and Cox regression. Results: The median follow‐up was 50 months. A G8 cut‐off of 9.75 was identified (AUC: 0.713, p < 0.01). Patients with G8 ≥ 9.75 showed significantly improved OS (median: 47 vs. 7 months, p < 0.01) and 4‐year CSS (66% vs. 32%, p < 0.01). In the definitive treatment group, 4‐year CSS was 68% in high‐G8 patients vs. 42% in low‐G8 patients. In the recurrence group, 4‐year CSS was 63% among high‐G8 patients, whereas no patient with a low G8 score survived beyond 4 years. Multivariate analysis identified G8 < 9.75 (HR: 4.72, p < 0.01) and RT dose < 60 Gy (HR: 3.01, p = 0.01) as independent predictors of poor OS. No significant association was observed between CCI and survival. Conclusion: The G8 score is a valuable prognostic tool for cisplatin‐ineligible HNSCC patients treated with RT and cetuximab. Low G8 scores were strongly associated with worse outcomes, highlighting the need for alternative therapeutic strategies in this high‐risk subgroup.
- Open Access
- 29 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 27653
The prognostic importance of neuronatin positivity as immunohistochemical in patients with lung adenocarcinoma in the development of brain metastasis
To search the prognostic significance of the neuronatin (NNAT) protein diagnosed with lung adenocarcinoma in the occurence of brain metastasis. Sixty-six of 200 patients diagnosed with lung adenocarcinoma who received radiotherapy (RT) between 2014 and 2017 were included in the study. A total of 66 patients, 33 (50%) with brain pathology and 33 (50%) with lung pathology, were analyzed retrospectively. Furthermore NNAT-immune-reactivity score (IRS) and nuclear positivity were analyzed in terms of pathological factors. In 33 cases where primary tumor pathology was studied, a statistically borderline significant effect was found for the N stage and a statistically significant effect on overall survival (OS) for nuclear positivity. While OS was 7.6 months in nucleus positively stained (PNS) cases, it was 24.4 months in negatively stained (NNS) cases. While the survival of NNAT-IRS positive cases without cranial metastasis was 20.7 months, the survival of the negative group without cranial metastasis was 61.2 months. The survival of cases with PNS without cranial metastasis was 7.1 months, while the survival of cases with NNS results without cranial metastasis was 52.1 months. In cases where intracranial pathologies, the number of intracranial metastases and the presence of extracranial metastases were found to be statistically significant independent factors (p < 0.001, p < 0.001). With NNAT study in initial pathological tissues of patients diagnosed with lung adenocarcinoma, especially nuclear positivity and NNAT-IRS positivity, a strong prediction can be made about the occurrence of brain metastasis.
- 29 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 27653
Open AccessThe prognostic importance of neuronatin positivity as immunohistochemical in patients with lung adenocarcinoma in the development of brain metastasis
To search the prognostic significance of the neuronatin (NNAT) protein diagnosed with lung adenocarcinoma in the occurence of brain metastasis. Sixty-six of 200 patients diagnosed with lung adenocarcinoma who received radiotherapy (RT) between 2014 and 2017 were included in the study. A total of 66 patients, 33 (50%) with brain pathology and 33 (50%) with lung pathology, were analyzed retrospectively. Furthermore NNAT-immune-reactivity score (IRS) and nuclear positivity were analyzed in terms of pathological factors. In 33 cases where primary tumor pathology was studied, a statistically borderline significant effect was found for the N stage and a statistically significant effect on overall survival (OS) for nuclear positivity. While OS was 7.6 months in nucleus positively stained (PNS) cases, it was 24.4 months in negatively stained (NNS) cases. While the survival of NNAT-IRS positive cases without cranial metastasis was 20.7 months, the survival of the negative group without cranial metastasis was 61.2 months. The survival of cases with PNS without cranial metastasis was 7.1 months, while the survival of cases with NNS results without cranial metastasis was 52.1 months. In cases where intracranial pathologies, the number of intracranial metastases and the presence of extracranial metastases were found to be statistically significant independent factors (p < 0.001, p < 0.001). With NNAT study in initial pathological tissues of patients diagnosed with lung adenocarcinoma, especially nuclear positivity and NNAT-IRS positivity, a strong prediction can be made about the occurrence of brain metastasis.
- Open Access
- 1 April 2025
- Published by Wiley in Head & Neck
- Vol. 47 (9) , 2383-2391
Ultra‐Hypofractionated Radiotherapy for Early‐Stage Glottic Cancer: Real‐World Data From a Single Center
Background: In recent years, smaller‐volume radiotherapy has attracted attention. It appears to be a safe and effective treatment for glottic laryngeal cancer. This study evaluated the results of ultra‐hypofractionated radiotherapy for early glottic laryngeal cancer in unfit patients. Methods: This retrospective study analyzed 22 patients diagnosed with early glottic cancer between June 2017 and January 2021. The involved vocal cord was treated with 35–42.5 Gy in 5 fractions. Results: On a 59‐month median follow‐up, the 5‐year overall survival and local control rate were 68.2% and 94.7%, respectively. However, the 5‐year larynx preservation rate was 89.7%. Chondronecrosis was observed in one patient (4.5%), and soft tissue necrosis in one patient (4.5%). PTV D98 (> 41.08 Gy) was found to be statistically significant in surgery‐needed events (HR: 22.4, 95% CI: 1.9–252.1, p = 0.01). Conclusion: Single‐cord ultra‐hypofractionated radiotherapy appears to be an effective treatment for local control. However, the risk of radionecrosis is higher at doses above 41.08 Gy.
- 1 April 2025
- Published by Wiley in Head & Neck
- Vol. 47 (9) , 2383-2391
Open AccessUltra‐Hypofractionated Radiotherapy for Early‐Stage Glottic Cancer: Real‐World Data From a Single Center
Background: In recent years, smaller‐volume radiotherapy has attracted attention. It appears to be a safe and effective treatment for glottic laryngeal cancer. This study evaluated the results of ultra‐hypofractionated radiotherapy for early glottic laryngeal cancer in unfit patients. Methods: This retrospective study analyzed 22 patients diagnosed with early glottic cancer between June 2017 and January 2021. The involved vocal cord was treated with 35–42.5 Gy in 5 fractions. Results: On a 59‐month median follow‐up, the 5‐year overall survival and local control rate were 68.2% and 94.7%, respectively. However, the 5‐year larynx preservation rate was 89.7%. Chondronecrosis was observed in one patient (4.5%), and soft tissue necrosis in one patient (4.5%). PTV D98 (> 41.08 Gy) was found to be statistically significant in surgery‐needed events (HR: 22.4, 95% CI: 1.9–252.1, p = 0.01). Conclusion: Single‐cord ultra‐hypofractionated radiotherapy appears to be an effective treatment for local control. However, the risk of radionecrosis is higher at doses above 41.08 Gy.
- Open Access
- 31 May 2024
- Published by Orclever Science and Research Group in The European Journal of Research and Development
- Vol. 4 (2) , 220-228
Brachytherapy Method Using Individualized Applicators to Increase Efficiency in Skin Tumors Treatment
Brachytherapy method using individualized applicators to increase efficiency in skin tumors treatment is presented. Skin tumors are one of the most common types of cancer in the world. Nonmelanoma skin basal cell and squamous cell skin carcinomas, known as NMSCs, are the most common cancers. The main purpose of this work is to comprehend basic treatment methods of skin tumors. The other purpose is to emphasize advantages and impact of the brachytherapy method using individualized applicators. Earlier skin tumor treatment methods are surgery and external (electron beam) radiotherapy. However, the brachytherapy method not widely used in skin tumor treatment process provides more efficient results due to the usage of individualized applicators specially produced for patients. Conclusively, individualized applicators provides more benefits and the fact that these applicators are improved much facilitates treatment process.
- 31 May 2024
- Published by Orclever Science and Research Group in The European Journal of Research and Development
- Vol. 4 (2) , 220-228
Open AccessBrachytherapy Method Using Individualized Applicators to Increase Efficiency in Skin Tumors Treatment
Brachytherapy method using individualized applicators to increase efficiency in skin tumors treatment is presented. Skin tumors are one of the most common types of cancer in the world. Nonmelanoma skin basal cell and squamous cell skin carcinomas, known as NMSCs, are the most common cancers. The main purpose of this work is to comprehend basic treatment methods of skin tumors. The other purpose is to emphasize advantages and impact of the brachytherapy method using individualized applicators. Earlier skin tumor treatment methods are surgery and external (electron beam) radiotherapy. However, the brachytherapy method not widely used in skin tumor treatment process provides more efficient results due to the usage of individualized applicators specially produced for patients. Conclusively, individualized applicators provides more benefits and the fact that these applicators are improved much facilitates treatment process.
- 10 May 2024
- Published by Springer Nature in Head and Neck Pathology
- Vol. 18 (1) , 1-9
The Depth of Invasion and Level IV Cervical Node Metastasis in Patients with Clinically N0 Tongue Cancer
Background The accurate indication for level IV dissection is crucial for preventing complications such as phrenic nerve damage and chylous fistulas in clinically N0 tongue cancer. Although the depth of invasion is an established independent risk factor for occult lymph node metastasis in tongue cancer, its relationship with level IV metastasis has not been evaluated. This study investigated the relationship between the depth of invasion and level IV nodal metastasis in clinically N0 tongue cancer. Methods We retrospectively investigated clinical N0 patients who underwent glossectomy and level I–IV neck dissection. We examined lymph node metastasis, risk factors, and the relationship between depth of invasion and metastasis. Results Our study included 58 patients, and no patient had isolated level IV metastasis. Additionally, there was no level IV metastasis in well-differentiated tumors. Tumor size, depth of invasion, differentiation, and perineural invasion were significantly associated with level IV neck metastasis. We found a critical tumor size of 2.5 cm and depth of invasion of 8 mm for level IV neck metastasis. Conclusion Based on our findings, we recommend that level IV dissection should be considered for poorly differentiated tumors, tumors greater than 2.5 cm in size, and those deeper than 8 mm. This study highlights the importance of depth of invasion as a prognostic factor for predicting level IV metastasis and suggests that our findings can be used to prevent unnecessary level IV dissections that may lead to complications in tongue cancer surgery.
- 10 May 2024
- Published by Springer Nature in Head and Neck Pathology
- Vol. 18 (1) , 1-9
The Depth of Invasion and Level IV Cervical Node Metastasis in Patients with Clinically N0 Tongue Cancer
Background The accurate indication for level IV dissection is crucial for preventing complications such as phrenic nerve damage and chylous fistulas in clinically N0 tongue cancer. Although the depth of invasion is an established independent risk factor for occult lymph node metastasis in tongue cancer, its relationship with level IV metastasis has not been evaluated. This study investigated the relationship between the depth of invasion and level IV nodal metastasis in clinically N0 tongue cancer. Methods We retrospectively investigated clinical N0 patients who underwent glossectomy and level I–IV neck dissection. We examined lymph node metastasis, risk factors, and the relationship between depth of invasion and metastasis. Results Our study included 58 patients, and no patient had isolated level IV metastasis. Additionally, there was no level IV metastasis in well-differentiated tumors. Tumor size, depth of invasion, differentiation, and perineural invasion were significantly associated with level IV neck metastasis. We found a critical tumor size of 2.5 cm and depth of invasion of 8 mm for level IV neck metastasis. Conclusion Based on our findings, we recommend that level IV dissection should be considered for poorly differentiated tumors, tumors greater than 2.5 cm in size, and those deeper than 8 mm. This study highlights the importance of depth of invasion as a prognostic factor for predicting level IV metastasis and suggests that our findings can be used to prevent unnecessary level IV dissections that may lead to complications in tongue cancer surgery.
- 16 April 2021
- Published by Academician Publishing
Onkolojide Görüntüleme ve Nükleer Tıp Temelli Tedaviler
- 16 April 2021
- Published by Academician Publishing
Onkolojide Görüntüleme ve Nükleer Tıp Temelli Tedaviler
- 10 August 2020
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 17 (1) , 43-51
MR‐guided simulation is superior than FDG/PET‐guided simulation for local control in nasopharyngeal cancer patients treated with intensity‐modulated radiotherapy
Background: MRI and PET/CT scans are the main supportive methods for nasopharyngeal cancer (NPC) for staging and planning. The aim of this study is to compare MRI and PET/CT scanning in terms of survival in patients with NPC who had MRI or PET/CT‐simulated radiotherapy planning.Methods: Pathological diagnosed nonkeratinized undifferentiated type and stage II‐IVA 91 NPC patients with treated intensity‐modulated radiotherapy plus chemotherapy were scanned. The patients were immobilized by a customized thermoplastic mask for fusion images both MRI scans and PET/CT scans. CTVs were created via MR‐guided simulation and PET/CT‐guided simulation.Results: PET/CT‐guided simulation was performed with 44 patients (56.4%) and MR‐guided simulation was performed with 34 patients (43.6%). Local recurrence‐free survival (LRFS) of patients was 68.1 months. LRFS of patients with PET/CT‐guided simulation was 59.9, while LRFS of patients with MR‐guided was 66.9 months. There was a statistically significant difference between groups (P = .03). In the subgroup analyses, the patients were assessed by dividing into the three groups for the T1‐T2 stage, T‐3 stage, and T‐4 stage. In the patients with T1‐T2 stage, 5‐year LRFS rates were found %74.4 for PET/CT‐guided simulation and %83.3 for MR‐guided simulation. There was no statistically significant difference between groups (P = .33). In the patients with T‐3 stage, 5‐year LRFS rates were found %55.6 for PET/CT‐guided simulation and %83.3 for MR‐guided simulation. There was not a statistically significant difference between groups (P = .59). In the patients with T‐4 stage, 5‐year LRFS rates were found %42.2 for PET/CT‐guided simulation and %85.1 for MR‐guided simulation. The difference between groups was found to be statistically significant (P = .04).Conclusion: In this study, we founded that MR‐guided simulation has better than PET/CT‐guided simulation for LRFS.
- 10 August 2020
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 17 (1) , 43-51
MR‐guided simulation is superior than FDG/PET‐guided simulation for local control in nasopharyngeal cancer patients treated with intensity‐modulated radiotherapy
Background: MRI and PET/CT scans are the main supportive methods for nasopharyngeal cancer (NPC) for staging and planning. The aim of this study is to compare MRI and PET/CT scanning in terms of survival in patients with NPC who had MRI or PET/CT‐simulated radiotherapy planning.Methods: Pathological diagnosed nonkeratinized undifferentiated type and stage II‐IVA 91 NPC patients with treated intensity‐modulated radiotherapy plus chemotherapy were scanned. The patients were immobilized by a customized thermoplastic mask for fusion images both MRI scans and PET/CT scans. CTVs were created via MR‐guided simulation and PET/CT‐guided simulation.Results: PET/CT‐guided simulation was performed with 44 patients (56.4%) and MR‐guided simulation was performed with 34 patients (43.6%). Local recurrence‐free survival (LRFS) of patients was 68.1 months. LRFS of patients with PET/CT‐guided simulation was 59.9, while LRFS of patients with MR‐guided was 66.9 months. There was a statistically significant difference between groups (P = .03). In the subgroup analyses, the patients were assessed by dividing into the three groups for the T1‐T2 stage, T‐3 stage, and T‐4 stage. In the patients with T1‐T2 stage, 5‐year LRFS rates were found %74.4 for PET/CT‐guided simulation and %83.3 for MR‐guided simulation. There was no statistically significant difference between groups (P = .33). In the patients with T‐3 stage, 5‐year LRFS rates were found %55.6 for PET/CT‐guided simulation and %83.3 for MR‐guided simulation. There was not a statistically significant difference between groups (P = .59). In the patients with T‐4 stage, 5‐year LRFS rates were found %42.2 for PET/CT‐guided simulation and %85.1 for MR‐guided simulation. The difference between groups was found to be statistically significant (P = .04).Conclusion: In this study, we founded that MR‐guided simulation has better than PET/CT‐guided simulation for LRFS.
- Open Access
- 1 January 2020
- Published by Kare Publishing in Turkish Journal of Trauma and Emergency Surgery
- Vol. 42 (4) , 386-394
Pretreatment Metabolic Tumor Volume of Primary Tumor and Total Lesion Glycolysis of Lymph Nodes are Predictive in Nasopharyngeal Cancer
- 1 January 2020
- Published by Kare Publishing in Turkish Journal of Trauma and Emergency Surgery
- Vol. 42 (4) , 386-394
Open AccessPretreatment Metabolic Tumor Volume of Primary Tumor and Total Lesion Glycolysis of Lymph Nodes are Predictive in Nasopharyngeal Cancer